Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AVTR
AVTR logo

AVTR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
7.649
Open
7.590
VWAP
7.44
Vol
7.06M
Mkt Cap
5.01B
Low
7.265
Amount
52.55M
EV/EBITDA(TTM)
9.05
Total Shares
676.11M
EV
8.63B
EV/OCF(TTM)
13.84
P/S(TTM)
0.77
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
Show More

Events Timeline

No data

No data

News

Fool
8.5
03-22Fool
Circumference Group Acquires New Position in Avantor
  • New Position Disclosure: Circumference Group disclosed a new position in Avantor by acquiring 305,000 shares worth $3.5 million in Q4 2026, reflecting confidence in the company despite a 54% decline in its stock price over the past year.
  • Asset Allocation Insight: This acquisition represents 3.77% of Circumference Group's 13F reportable assets, indicating a strategic positioning within a diversified portfolio, particularly in light of ongoing demand in the biopharma and advanced technology sectors.
  • Company Financial Overview: Avantor reported over $6.5 billion in revenue for the full year 2025, with quarterly sales down 1%, yet adjusted EBITDA exceeding $1 billion highlights its potential for stable cash flow, especially with management's “Revival” program underway.
  • Market Outlook Analysis: The stable demand for lab consumables and the management's focus on execution improvements may position Avantor as a strong cash generator in the future, attracting long-term investors' interest amidst ongoing production workflow needs.
NASDAQ.COM
8.5
03-22NASDAQ.COM
Circumference Group Acquires Shares in Avantor
  • New Investment Position: Circumference Group initiated a new position in Avantor by acquiring 305,000 shares worth $3.5 million during Q4 2026, reflecting confidence in the company despite its 3.77% portfolio allocation.
  • Financial Performance Review: Avantor reported a 1% decline in quarterly sales to $1.66 billion, with full-year revenue exceeding $6.5 billion, but faced a full-year loss due to one-time charges, indicating pressure on profitability.
  • Management Revival Program: Avantor is implementing a 'Revival' program aimed at addressing execution and cost structure issues, focusing on go-to-market strategies and supply chain improvements, which could help restore margins and enhance cash flow if successful.
  • Market Position Advantage: Unlike high-growth biotech firms, Avantor benefits from stable demand for lab consumables and production workflows, making it crucial for long-term investors to monitor its ability to recover margins without sacrificing volume.
Fool
6.5
03-16Fool
Eversept Partners Increases Stake in Avantor
  • Share Increase: Eversept Partners disclosed a purchase of 2,252,202 shares of Avantor in Q4 2025, valued at approximately $27.72 million, indicating confidence in the company's future despite a 50% decline in stock price over the past year.
  • Holding Status: Following the acquisition, Eversept's total holdings in Avantor reached 3,176,644 shares worth $36.40 million, representing 1.83% of its U.S. equity portfolio, though it remains outside the top five positions.
  • Financial Performance: Avantor reported a revenue of $6.55 billion for 2025, a 3% decline year-over-year, alongside a net loss of $530.2 million, with the CEO emphasizing the importance of the
Globenewswire
7.0
03-12Globenewswire
Johnson Fistel Investigates Executive Liability for Multiple Companies
  • Shareholder Rights Investigation: Johnson Fistel is investigating potential breaches of fiduciary duty by executives at Avantor, Baxter, Biogen, and CarMax, which may lead shareholders to seek corporate governance reforms and fund recovery.
  • Avantor Allegations: A lawsuit against Avantor claims that executives failed to disclose a decline in competitive positioning and negative competitive impacts, leading to shareholder misconceptions about the company's prospects, potentially affecting its stock price.
  • Baxter Product Defects: Baxter's Novum LVP product is alleged to have systemic defects that pose serious risks to patients, and the company's inadequate response to these defects may result in significant legal and financial repercussions.
  • Biogen Transparency Issues: Biogen is accused of overstating its efforts to enhance transparency and compliance controls, failing to disclose improper conduct in foreign operations, which could lead to regulatory scrutiny and reputational harm.
Benzinga
8.5
03-10Benzinga
Emerging Consolidation Wave in U.S. Markets
  • Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
  • Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
  • Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
  • Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
NASDAQ.COM
8.0
03-06NASDAQ.COM
Surge in Options Trading Volume for Alphabet and ArriVent
  • Alphabet Options Volume: Alphabet Inc (GOOGL) saw options trading volume of 286,878 contracts today, representing approximately 28.7 million shares, which is about 71.2% of its average daily trading volume of 40.3 million shares over the past month, indicating strong market interest in its future performance.
  • High Volume Analysis: Notably, the $300 strike call option has seen 21,691 contracts traded today, equating to approximately 2.2 million shares, reflecting bullish investor sentiment regarding GOOGL's prospects before the March 2026 expiration.
  • ArriVent Options Activity: Concurrently, ArriVent Biopharma Inc (AVBP) recorded an options trading volume of 3,090 contracts today, representing about 309,000 shares, which is approximately 71.1% of its average daily trading volume of 434,360 shares over the past month, showcasing market interest in its growth potential.
  • Strike Price Focus: For AVBP, the $22.50 strike call option has seen a trading volume of 2,018 contracts today, translating to around 201,800 shares, indicating optimistic investor expectations for its performance ahead of the April 2026 expiration.
Wall Street analysts forecast AVTR stock price to rise
7 Analyst Rating
Wall Street analysts forecast AVTR stock price to rise
1 Buy
4 Hold
2 Sell
Hold
Current: 0.000
sliders
Low
8.00
Averages
11.67
High
16.00
Current: 0.000
sliders
Low
8.00
Averages
11.67
High
16.00
Barclays
Equal Weight -> Underweight
downgrade
AI Analysis
2026-03-06
Reason
Barclays
Price Target
AI Analysis
2026-03-06
downgrade
Equal Weight -> Underweight
Reason
Barclays downgraded Avantor to Underweight from Equal Weight with an $8.50 price target.
Barclays
Luke Sergott
Equal Weight -> Underweight
downgrade
$9
2026-03-06
Reason
Barclays
Luke Sergott
Price Target
$9
2026-03-06
downgrade
Equal Weight -> Underweight
Reason
Barclays analyst Luke Sergott downgraded Avantor to Underweight from Equal Weight with a price target of $8.50, down from $9. The firm says that when investors come back to the tools space, they are going to go to "large-cap bellwethers that have been caught up in the AI craze." Avantor's business is seeing share losses, a lack of investment, and questions if " management can right the ship," the analyst tells investors in a research note. Barclays believes investors will not look to the shares when they come back to tools.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AVTR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Avantor Inc (AVTR.N) is 12.99, compared to its 5-year average forward P/E of 20.28. For a more detailed relative valuation and DCF analysis to assess Avantor Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
20.28
Current PE
12.99
Overvalued PE
24.99
Undervalued PE
15.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
15.45
Current EV/EBITDA
10.90
Overvalued EV/EBITDA
18.14
Undervalued EV/EBITDA
12.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.18
Current PS
1.20
Overvalued PS
2.71
Undervalued PS
1.66

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stocks with biggest losses
Intellectia · 43 candidates
Market Cap: >= 300.00MRegion: USPrice: >= $2.00Volume: >= 300,000Price Change Pct: <= $-10.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
U logo
U
Unity Software Inc
9.27B
MAT logo
MAT
Mattel Inc
4.91B
ANGI logo
ANGI
Angi Inc
396.99M
LEU logo
LEU
Centrus Energy Corp
4.13B
ZG logo
ZG
Zillow Group Inc
10.92B
LYFT logo
LYFT
Lyft Inc
5.61B
best 3 stocks under $20 to buy tomorrow
Intellectia · 166 candidates
Market Cap: >= 500.00MPrice: <= $20.00Beta: ModerateRiskWeekly Average Turnover: >= 1,000,000Rsi 14: 30 - 70
Ticker
Name
Market Cap$
top bottom
LYG logo
LYG
Lloyds Banking Group PLC
81.38B
NWG logo
NWG
NatWest Group PLC
70.55B
STLA logo
STLA
Stellantis NV
37.25B
NOK logo
NOK
Nokia Oyj
35.71B
ERIC logo
ERIC
Telefonaktiebolaget LM Ericsson
31.60B
WIT logo
WIT
Wipro Ltd
27.24B

Whales Holding AVTR

R
RobecoSAM AG
Holding
AVTR
+8.93%
3M Return
N
NewSouth Capital Management, Inc.
Holding
AVTR
+5.64%
3M Return
B
Barrow, Hanley, Mewhinney & Strauss, LLC
Holding
AVTR
+3.25%
3M Return
P
Private Management Group Inc
Holding
AVTR
+3.20%
3M Return
C
Clarkston Capital Partners, LLC
Holding
AVTR
-3.96%
3M Return
G
Greenhaven Associates Inc
Holding
AVTR
-5.97%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Avantor Inc (AVTR) stock price today?

The current price of AVTR is 7.41 USD — it has decreased -3.39

What is Avantor Inc (AVTR)'s business?

Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.

What is the price predicton of AVTR Stock?

Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is11.67 USD with a low forecast of 8.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Avantor Inc (AVTR)'s revenue for the last quarter?

Avantor Inc revenue for the last quarter amounts to 1.66B USD, decreased -1.36

What is Avantor Inc (AVTR)'s earnings per share (EPS) for the last quarter?

Avantor Inc. EPS for the last quarter amounts to 0.08 USD, decreased -89.04

How many employees does Avantor Inc (AVTR). have?

Avantor Inc (AVTR) has 13500 emplpoyees as of March 30 2026.

What is Avantor Inc (AVTR) market cap?

Today AVTR has the market capitalization of 5.01B USD.